FDA Approves GSK's Hibsago, First Antisense Drug for Hepatitis B

FDA approved GSK's Hibsago (bepirovirsen) on 20 October 2026 for chronic hepatitis B in a defined adult population — six days ahead of its 26 October PDUFA target action date. It is the first antisense oligonucleotide cleared for the indication, and the first new mechanism for chronic HBV in years: not a replacement for existing antivirals, but an add-on aimed at a goal current therapy rarely reaches — stopping treatment altogether.

What Hibsago is, and what it is not

Bepirovirsen is an antisense oligonucleotide: a short synthetic strand designed to bind HBV messenger RNA and reduce production of the viral surface antigen (HBsAg) and other viral proteins, rather than blocking viral replication the way existing nucleos(t)ide analogues (NAs) — entecavir, tenofovir and similar drugs — do. It is not a replacement for NA therapy on approval day. The label covers adults who have already been stabilized on an NA for at least six months, with HBV DNA suppressed and HBsAg at or below 3000 IU/mL, and Hibsago is added to that existing regimen rather than substituted for it. GSK licensed bepirovirsen from Ionis Pharmaceuticals, whose antisense chemistry underlies the drug.

The trial data, and why the two endpoints matter separately

Chronic hepatitis B treatment today is mostly open-ended: NAs suppress the virus effectively but rarely eliminate HBsAg, so most patients stay on therapy indefinitely. Bepirovirsen's Phase 3 program — B-Well 1 and B-Well 2 — tested two related but distinct outcomes. The first was whether patients could stop their NA therapy at all: patients continued their background NA through week 48, and NA was discontinued only for those who had reached undetectable HBV DNA and undetectable HBsAg by that point. Across the pooled trials, 24% of bepirovirsen recipients met that bar, against none of the placebo group. The second, more stringent endpoint was functional cure — sustained undetectable HBsAg and HBV DNA without any treatment — assessed 24 weeks after all therapy stopped, around week 72. There, the pooled rate was 19% (233 of 1,220 patients) versus 0% (0 of 614) on placebo, with per-trial results of 20% in B-Well 1 and 19% in B-Well 2. The rate rose to 26% in patients who started with lower baseline HBsAg (≤1000 IU/mL). A functional cure is not the same as eliminating the virus from the body entirely — HBV can persist in a latent form — but it is the outcome hepatologists use as the practical treatment goal, since it is associated with durable remission and no further antiviral requirement.

Safety and the practical administration picture

The most frequently reported adverse reactions, excluding routine laboratory abnormalities, were injection site reactions, pyrexia, fatigue and headache — consistent with other subcutaneously administered antisense and siRNA therapies. FDA's labeling also carries warnings for worsening renal function and for serious inflammatory reactions, including vasculitis, along with risks tied to improper self-administration. Reporting on the approval indicates patients may be able to self-administer after an initial dose under supervision, which would matter for a drug given over a defined, extended course rather than as a one-time intervention — though the exact dosing schedule and administration-site specifics belong in the full prescribing information rather than in secondary summaries.

What this changes operationally

• Patient identification: the eligible population is narrow by design — non-cirrhotic adults already stable on NA therapy for six months or more, with suppressed HBV DNA and HBsAg at or under 3000 IU/mL. Practices should expect a screening and eligibility-confirmation step before any prescribing conversation, not a broad switch for the existing HBV panel.
• Stopping rules: the approval's clinical logic runs through two checkpoints — a week-48 assessment for background-NA discontinuation eligibility, and a week-72 (24-weeks-post-treatment) assessment for functional cure — so monitoring protocols built around Hibsago will need to track both, not just viral suppression.
• Market context: this is the first antisense therapy approved for chronic hepatitis B and the first new mechanism to reach approval in the indication in some time; expect formulary and prior-authorization criteria to take time to catch up to a narrower-than-NA-class label.
• Japan precedent: bepirovirsen has already been approved in Japan, which regulatory teams tracking multi-region rollout timing should note alongside the US action.

What is not yet settled

FDA granted the approval under priority review with Breakthrough Therapy designation, six days ahead of the PDUFA date GSK had previously disclosed, which is itself unremarkable for a priority-review action but worth noting for sponsors tracking FDA's recent pace on breakthrough-designated antivirals. What the public reporting to date does not establish is the complete label language — exact dosing regimen, treatment duration, and the full monitoring schedule belong in FDA's official prescribing information once published, not in secondary trade coverage, and regulatory and medical affairs teams should confirm against that primary document before building patient-facing materials.

Frequently asked questions

What did FDA approve, and when?

On 20 October 2026, FDA approved Hibsago (bepirovirsen), GSK's antisense oligonucleotide, for chronic hepatitis B in adults — six days ahead of its 26 October 2026 PDUFA date. It is the first antisense therapy approved for this indication.

Who is eligible for Hibsago?

Adults with chronic hepatitis B, without cirrhosis, who have been on a nucleos(t)ide analogue (NA) antiviral for at least six months, have suppressed HBV DNA, and have HBsAg levels of 3000 IU/mL or less, given alongside the existing NA therapy.

How effective was it in trials?

Pooled B-Well 1/B-Well 2 data: 19% functional cure 24 weeks after stopping all treatment versus 0% on placebo (26% in the ≤1000 IU/mL HBsAg subgroup); separately, 24% met criteria to discontinue background antiviral therapy at week 48, versus none on placebo.

What are the main safety concerns?

Most common adverse reactions: injection site reactions, pyrexia, fatigue and headache. Labeling carries warnings for worsening renal function and serious inflammatory reactions, including vasculitis.